Phoenix Bio

研究開発

研究開発

Synthetic lipophilic antioxidant BO-653 suppresses HCV replication.

    Yasui F, Sudoh M, Arai M, Kohara M.
    J Med Virol. 2013 Feb;85(2):241-9.

    Novel cell culture-adapted genotype 2a hepatitis C virus infectious clone.

      Date T, Kato T, Kato J, Takahashi H, Morikawa K, Akazawa D, Murayama A, Tanaka-Kaneko K, Sata T, Tanaka Y, Mizokami M, Wakita T.
      J Virol. 2012 Oct;86(19):10805-20.

      An orally available, small-molecule interferon inhibits viral replication

        Hideyuki Konishi, Koichi Okamoto, Yusuke Ohmori, Hitoshi Yoshino, Hiroshi Ohmori, Motooki Ashihara, Yuichi Hirata, Atsunori Ohta, Hiroshi Sakamoto, Natsuko Hada, Asao Katsume, Michinori Kohara, Kazumi Morikawa, Takuo Tsukuda, Nobuo Shimma, Graham R. Foster, William Alazawi, Yuko Aoki, Mikio Arisawa & Masayuki Sudoh
        Scientific Reports Volume: 2,Article number:259

        Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor.

          Sainz B Jr, Barretto N, Martin DN, Hiraga N, Imamura M, Hussain S, Marsh KA, Yu X, Chayama K, Alrefai WA, Uprichard SL.
          Nat Med. 2012 Jan 8;18(2):281-5

          Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice

            Ype P. de Jong1,2, Charles M. Rice1, Alexander Ploss1,

            J Hepatol.2011; 54:848–850

             

            Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus.

              Hiraga N, Abe H, Imamura M, Tsuge M, Takahashi S, Hayes CN, Ochi H, Tateno C, Yoshizato K, Nakamura Y, Kamatani N, Chayama K.
              Hepatology. 2011 Sep 2;54(3):764-71.

              Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.

                Hiraga N, Imamura M, Abe H, Hayes CN, Kono T, Onishi M, Tsuge M, Takahashi S, Ochi H, Iwao E, Kamiya N, Yamada I, Tateno C, Yoshizato K, Matsui H, Kanai A, Inaba T, Tanaka S, Chayama K.
                Hepatology. 2011 Sep 2;54(3):781-8.

                Augmentation of DHCR24 expression by hepatitis C virus infection facilitates viral replication in hepatocytes.

                  Takano T, Tsukiyama-Kohara K, Hayashi M, Hirata Y, Satoh M, Tokunaga Y, Tateno C, Hayashi Y, Hishima T, Funata N, Sudo M, Kohara M.

                  J Hepatol. 2011 Sep;55(3):512-21

                   

                  ME3738 enhances the effect of interferon and inhibits hepatitis C virus replication both in vitro and in vivo.

                    Abe H, Imamura M, Hiraga N, Tsuge M, Mitsui F, Kawaoka T, Takahashi S, Ochi H, Maekawa T, Hayes CN, Tateno C, Yoshizato K, Murakami S, Yamashita N, Matsuhira T, Asai K, Chayama K.
                    J Hepatol. 2011 Jul;55(1):11-8. Epub 2010 Nov 29.

                    EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy.

                      Lupberger J, Zeisel MB, Xiao F, Thumann C, Fofana I, Zona L, Davis C, Mee CJ, Turek M, Gorke S, Royer C, Fischer B, Zahid MN, Lavillette D, Fresquet J, Cosset FL, Rothenberg SM, Pietschmann T, Patel AH, Pessaux P, Doffoël M, Raffelsberger W, Poch O, McKea
                      Nat Med. 2011 May;17(5):589-95.

                      Elimination of hepatitis C virus by short term NS3-4A and NS5B inhibitor combination therapy in human hepatocyte chimeric mice.

                        Ohara E, Hiraga N, Imamura M, Iwao E, Kamiya N, Yamada I, Kono T, Onishi M, Hirata D, Mitsui F, Kawaoka T, Tsuge M, Takahashi S, Abe H, Hayes CN, Ochi H, Tateno C, Yoshizato K, Tanaka S, Chayama K.
                        J Hepatol. 2011 May;54(5):872-8

                        Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants.

                          Mishima K, Sakamoto N, Sekine-Osajima Y, Nakagawa M, Itsui Y, Azuma S, Kakinuma S, Kiyohashi K, Kitazume A, Tsuchiya K, Imamura M, Hiraga N, Chayama K, Wakita T, Watanabe M.

                          Virology. 2010 Sep 30;405(2):361-9.

                          Positive selection of core 70Q variant genotype 1b hepatitis C virus strains induced by pegylated interferon and ribavirin.

                            Kurbanov F, Tanaka Y, Matsuura K, Sugauchi F, Elkady A, Khan A, Hasegawa I, Ohno T, Tokuda H, Mizokami M.

                            J Infect Dis. 2010 Jun 1;201(11):1663-71

                            Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver.

                              Kikuchi R, McCown M, Olson P, Tateno C, Morikawa Y, Katoh Y, Bourdet DL, Monshouwer M, Fretland AJ.
                              Drug Metab Dispos. 2010 Nov;38(11):1954-61.

                              Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.

                                Kamiya N, Iwao E, Hiraga N, Tsuge M, Imamura M, Takahashi S, Miyoshi S, Tateno C, Yoshizato K, Chayama K.
                                J Gen Virol. 2010 Jul;91(Pt 7):1668-77. Epub 2010 Feb 17.

                                Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry.

                                  Matsumura T, Hu Z, Kato T, Dreux M, Zhang YY, Imamura M, Hiraga N, Juteau JM, Cosset FL, Chayama K, Vaillant A, Liang TJ.
                                  Gastroenterology. 2009 Aug;137(2):673-81

                                  Adoptive immunotherapy with liver allograft-derived lymphocytes induces anti-HCV activity after liver transplantation in humans and humanized mice.

                                    Ohira M, Ishiyama K, Tanaka Y, Doskali M, Igarashi Y, Tashiro H, Hiraga N, Imamura M, Sakamoto N, Asahara T, Chayama K, Ohdan H.

                                    J Clin Invest. 2009 Nov;119(11):3226-35.

                                    Molecular epidemiology and interferon susceptibility of the natural recombinant hepatitis C virus strain RF1_2k/1b.

                                      Kurbanov F, Tanaka Y, Chub E, Maruyama I, Azlarova A, Kamitsukasa H, Ohno T, Bonetto S, Moreau I, Fanning LJ, Legrand-Abravanel F, Izopet J, Naoumov N, Shimada T, Netesov S, Mizokami M.
                                      J Infect Dis. 2008 Nov 15;198(10):1448-56.

                                      Establishment of an infectious genotype 1b hepatitis C virus clone in human hepatocyte chimeric mice.

                                        Kimura T, Imamura M, Hiraga N, Hatakeyama T, Miki D, Noguchi C, Mori N, Tsuge M, Takahashi S, Fujimoto Y, Iwao E, Ochi H, Abe H, Maekawa T, Arataki K, Tateno C, Yoshizato K, Wakita T, Okamoto T, Matsuura Y, Chayama K.
                                        J Gen Virol. 2008 Sep;89(Pt 9):2108-13.

                                        Single lymphocyte analysis with a microwell array chip.

                                          Tokimitsu Y, Kishi H, Kondo S, Honda R, Tajiri K, Motoki K, Ozawa T, Kadowaki S, Obata T, Fujiki S, Tateno C, Takaishi H, Chayama K, Yoshizato K, Tamiya E, Sugiyama T, Muraguchi A.
                                          Cytometry A, 2007 Dec;71(12):1003-10.